The purpose of the study was to determine if survival differences exist between 3 cycles of bleomycin, etoposide, and cisplatin (BEP 3 3) versus 4 cycles of etoposide and cisplatin (EP 3 4) for good-risk testicular cancer patients. In 223 patients, we found a nonsignificant trend toward improved survival when men were treated with BEP 3 3 compared with EP 3 4. Background: Patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk testicular cancer might receive either 4 cycles of etoposide and cisplatin (EP Â 4) or 3 cycles of bleomycin, etoposide, and cisplatin (BEP Â 3). We sought to examine differences in survival after retroperitoneal lymph node dissection (PC-RPLND) between patients who received EP Â 4 compared with BEP Â 3. Patients and Methods: The Indiana University Testis Cancer database was queried to identify IGCCCG good-risk PC-RPLND patients who received either EP Â 4 or BEP Â 3 induction chemotherapy. The primary outcome was overall survival (OS). KaplaneMeier plots were generated for the EP Â 4 and BEP Â 3 groups and compared using the log rank test. Cox regression analysis was used to determine risk of mortality. Results: A total of 223 patients met inclusion criteria between 1985 and 2011. Induction chemotherapy consisted of EP Â 4 in 45 (20%) patients and BEP Â 3 in 178 (80%). Most patients (78%) received their chemotherapy at outside institutions and were subsequently referred for PC-RPLND. The location of treating institution did not influence outcomes significantly when similar chemotherapy regimens were compared in this good-risk cohort. The 10-year OS for the EP Â 4 and BEP Â 3 groups were 91% and 98%, respectively (log rank P < .01). The adjusted risk of death in the EP Â 4 group showed a nonsignificant trend of 3 times greater compared with the BEP Â 3 group (hazard ratio, 3.1; 95% confidence interval, 0.8-12.0; P ¼ .10). Conclusion: The regimen of BEP Â 3 resulted in a trend toward improved survival, however, this did not reach statistical significance. The location of treating institution seems less important in this risk group of patients.
Introduction
The National Comprehensive Cancer Network currently recommends either 3 courses of BEP (bleomycin, etoposide, and cisplatin; BEP Â 3) or 4 courses of EP (etoposide and cisplatin; EP Â 4) for good-risk metastatic testicular cancer. 1 This recommendation is on the basis of randomized trial data that have sought to decrease morbidity and maintain efficacy in this subgroup of patients with excellent cure rates. [2] [3] [4] In phase III trials, BEP Â 3 was numerically superior, but not statistically significant in overall survival (OS).
Only a portion of patients in those randomized trials went on to postchemotherapy (PC) retroperitoneal (RP) lymph node dissection (RPLND). Further subdividing good-risk patients into those who required PC-RPLND for residual RP masses provides insight into treatment responses. Our institution recently published data on the histologic response of RP tumors to induction chemotherapy which showed higher proportions of active cancer in the EP Â 4 group compared with the BEP Â 3 group. 7 However, comparisons in OS between BEP Â 3 and EP Â 4 in the subgroup with residual RP masses that require PC-RPLND are limited in the literature.
In this retrospective study we evaluated OS in good-risk patients who underwent PC-RPLND and received either BEP Â 3 or EP Â 4.
Patients and Methods
The prospectively maintained Indiana University Testis Cancer database was queried to identify patients who underwent a PC-RPLND from 1985 to 2011. A total of 1815 patients were identified. Exclusion criteria included induction chemotherapy other than BEP or EP (n ¼ 352), International Germ Cell Cancer Collaborative Group (IGCCCG) intermediate-or poor-risk classification (n ¼ 593), or unavailable serum tumor markers (n ¼ 321), any combination of BEP and EP regimens (n ¼ 323). Three additional patients were excluded because of unclear risk category, nonstandard radiotherapy use, and findings of primitive neuroectodermal tumor. The remaining 223 patients with goodrisk disease who received either BEP Â 3 or EP Â 4 with all available data points made up the study cohort. These patients had received only the induction chemotherapy regimen and serum tumor markers had normalized before RPLND. The primary outcome of this study was OS. Death was determined according to chart review, referring physician confirmation, or National Death Index data. Long Term Survival After PCRPLND: BEPx3 vs. EPx4
Clinical and pathologic characteristics were determined by electronic and paper chart review. These variables included age at surgery, year of surgery, year of diagnosis, receipt of chemotherapy at Indiana (yes/no), histology of primary tumor, prechemotherapy serum tumor markers, prechemotherapy RP mass size, preoperative RP mass size, and RP histology. OS time was calculated from the date of surgery until the date of death or the last date the National Death Index was queried.
Pearson c 2 , Fisher exact test, and the Student t test were used to compare clinical and pathologic differences between groups. Continuous variables that were not normally distributed were evaluated using the ManneWhitney U test. KaplaneMeier plots were generated for the EP Â 4 and BEP Â 3 groups and compared using the log rank test. To determine if differences existed according to location where chemotherapy was delivered (Indiana University vs. outside institution) or if there were differences between those who were not treated with chemotherapy at Indiana University, sensitivity analyses were performed to evaluate the potential effect on RP histology and OS.
Multivariable analysis was performed using the Cox proportional hazard regression model. The primary outcome was death. All deaths were caused by disseminated germ cell tumor or treatmentrelated side effects. To account for baseline differences between treatment groups, propensity scores were generated using logistic regression for the propensity to receive EP Â 4. Variables included in the logistic regression model to generate propensity scores were determined a priori as potential confounders and included age, date of diagnosis, histology of primary site, prechemotherapy serum tumor markers, and prechemotherapy RP mass size. This generated a propensity score for each patient to determine the predicted probability for each patient to have received EP Â 4. Overlap in propensity scores were assessed between groups using histogram plots. Because of the low event rate, the multivariable Cox regression model only included the propensity score variable and the primary covariate of interest (ie, EP vs. BEP), to generate the most parsimonious model. Univariable and propensity score-adjusted Cox proportional hazard regression models were created to evaluate the association between induction chemotherapy regimen and OS. The proportional hazards assumption was tested using Schoenfeld residuals. All statistical tests were 2-sided with significance at P < .05. Stata (version 12.1 IC) statistical software (StataCorp, College Station, TX) was used to conduct the analyses. This study was approved by the Indiana University institutional review board.
Results
A total of 178 patients who received BEP Â 3 induction chemotherapy were identified and compared with 45 who received EP Â 4. The bleomycin cohort was younger, diagnosed and treated in earlier years, and was more likely to receive induction chemotherapy at Indiana University (all P < .003; Table 1 ). All 45 patients who received EP Â 4 were treated with chemotherapy at outside institutions. Patients who received EP Â 4 were treated according to the referring medical oncologist preferences before presenting to Indiana. None of the 45 patients had underlying lung disease prohibitive for receiving bleomycin on the basis of medical record review; however, 7 patients in the EP group were 50 years old or older.
There was no difference in RP mass size between the 2 groups either before chemotherapy or in the preoperative setting ( Table 1) . The preoperative RP mass size was >5 cm in 56 of the 178 (32%) patients who received BEP Â 3 compared with 14 of 45 (31%) patients who received EP Â 4. The patients who received BEP Â 3 had active cancer in 13 (7.8%) patient PC-RPLND specimens compared with 14 (31.9%) patients who received EP Â 4. Additionally, 115 patients (65%) who received BEP Â 3 were found to have teratoma in the RP specimen compared with 21 patients (47%) who received EP Â 4 (P < .001). Table 2 shows the RP histology of the 175 patients treated with chemotherapy outside of Indiana University. This again shows the increased proportion of patients in the EP Â 4 group (31%) having active cancer compared with only 9% in the BEP Â 3 group (P ¼ .002). We then evaluated if there was any RP histology differences between those who received BEP Â 3 at Indiana compared 
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with those who received BEP Â 3 at outside institutions (Table 2 ). There were no statistical differences in RP histology noted in these 2 groups (P ¼ .29).
Overall, there were 13 deaths during a median follow-up of 127 months. Of the 178 patients treated with BEP Â 3, 7 (4%) died of disease. Conversely, of the 45 patients treated with EP Â 4, 6 (13%) died of disease. Of the 13 deaths, 12 were due to recurrent germ cell tumor. The other patient died from complications related to myelodysplastic syndrome. This patient was treated with salvage TIP (paclitaxel, ifosfamide, cisplatin), then with high-dose chemotherapy and stem cell transplantation. The 10-year OS for the entire cohort was 97% (95% confidence interval [CI], 94-99). The 10-year OS for patients who received EP Â 4 was 91% (95% CI, 78-97) compared with 98% for those who received BEP Â 3 (95% CI, 93-99; P < .001; Figure 1 ). In patients found to have active cancer in the PC-RPLND specimen, the 10-year OS was 54% in the EP Â 4 group (95% CI, 17-80) compared with 89% in the BEP Â 3 group (95% CI, 43-98). Those patients who did not have active cancer in the RP specimen did very well regardless of chemotherapy regimen with long-term survival approaching 100% (Figure 2) . The unadjusted risk of death was 7.6 times higher in the EP Â 4 group compared with the BEP Â 3 group (hazard ratio [HR], 7.6; 95% CI, 2.26-25.4; P ¼ .001). After propensity score adjustment, the risk of death in the EP Â 4 group was 3 times higher, however, this was no longer statistically significant (HR, 3.1; 95% CI, 0.8-12.0; P ¼ .10; Table 2 ). To further assess the effect of age we performed KaplaneMeier sensitivity analyses stratified according to age older or younger than 40 years, which showed no differences in results. Additionally, we added age as a covariate in our propensity scoreadjusted Cox model with no significant change in results.
There were 4 seminoma patients who had an elevated alphafetoprotein level at presentation and 2 patients had biopsies of neck masses consistent with teratoma. For this reason, we also a conducted a sensitivity analysis excluding all seminoma patients and the survival results were unchanged. Figure 3 shows OS on the basis of location where chemotherapy was delivered. Figure 3A depicts a worse survival for patients treated with EP Â 4 treated outside Indiana compared with BEP Â 3 patients treated outside Indiana; log rank P ¼ .004. Figure 3B shows a borderline statistically worse survival in patients treated with BEP Â 3 outside Indiana compared with patients treated with BEP Â 3 at Indiana (P ¼ .05). However, these curves are almost mirror images of each other and thus might not be of clinical significance.
Discussion
This study has 2 main findings. First, the unadjusted OS for good-risk patients who underwent a PC-RPLND was worse for those who received EP Â 4 compared with BEP Â 3. However, the difference in survival became nonsignificant after propensity score adjustment, despite a continued trend for worse survival. This trend of worse survival is interesting because of the increased proportion of patients having active residual germ cell tumor found in the RP specimen in the EP Â 4 group. Second, the effect of treating institution (Indiana vs. outside) did not seem to have a large effect on survival in this good-risk cohort of patients in a comparison of similar chemotherapy regimens.
These data add to the published literature showing a numerically superior advantage of including bleomycin in the induction chemotherapy regimen. [4] [5] [6] In the phase III French trial that compared BEP Â 3 with EP Â 4, Culine et al 6 showed the 4-year OS to be numerically worse in the EP Â 4 group (93% vs. 97%; P ¼ .082). The randomized Eastern Cooperative Oncology Group trial that compared BEP Â 3 with EP for 3 cycles also showed a worse OS for the EP group (86% vs. 95%; P ¼ .01), albeit this trial only used 3 cycles of EP. 4 More recently, in a retrospective study from Memorial Sloan Kettering Cancer Center (MSKCC) IGCCCG good-risk patients treated with BEP Â 3 were compared with those treated with EP Â 4 who subsequently underwent a PC-RPLND. 8 This study also showed a small numerically but not 
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Clinical Genitourinary Cancer April 2018 -e311 statistically worse disease-free survival in patients who received EP Â 4 compared with the BEP Â 3 group (98% vs. 100%; P ¼ .32). The numerically superior survival in the BEP group in the current study is likely a function of the RP histology at the time of PC-RPLND. Only 7% of those treated with BEP had residual germ cell cancer in the RP specimen compared with 31% of patients treated with EP. Without robust randomized trial data with adequate power and follow-up, tumor response rates should be used as a surrogate for treatment efficacy. Patients with residual cancer in the retroperitoneum after induction chemotherapy have shown a decreased progression-free survival (PFS) and OS. Fizazi et al reported that patient with >10% viable cancer in PC residual masses had a PFS and OS of 55% and 63%, respectively, compared with 71% and 82% in residual masses with <10% viable cancer. 9 An
Indiana University study showed that of the 34 patients with viable cancer in the completely resected PC-RPLND specimen, 27 received postoperative cisplatin-based chemotherapy. There were 7 patients who did not receive postoperative chemotherapy, all of whom had disease relapse. 10 Spiess et al reported that presence of viable tumor in the PC-RPLND specimen was a predictor of PFS (P ¼ .03). 11 In our current series, patients in the EP Â 4 group had increased rates of active cancer in their PC-RPLND specimens and a trend toward decreased survival. An MSKCC study showed disparate results regarding RP histologic findings compared with our current study. In the MSKCC cohort, rates of viable cancer in the PC-RPLND specimens were 6% in the EP Â 4 group versus 5% in the BEP Â 3 group. 8 Preoperative lymph node sizes varied significantly between the 2 groups in the MSKCC study. Seventy percent of patients in the EP group had lymph nodes <2 cm compared with only 35% in the BEP Â 3 group. Eight percent of patients in the EP Â 4 group had lymph nodes >5 cm compared with 27% in the BEP Â 3 group. Despite this difference in preoperative RP mass size, the BEP Â 3 group had a lower rate of viable cancer in the PC-RPLND specimens. Furthermore, the suggestion that BEP leads to a biological development of teratoma in the retroperitoneum is unfounded. This is more likely a statistical issue after the exclusion of multiple patients treated with BEP Â 4, patients with masses greater than 1.1 cm, and limited outcome events resulting in an overfit logistic model. This is evidenced by the extremely wide CIs in that study.
In an evaluation of the effect of treating institution on outcomes, we did not observe large differences on the basis of where patients received their induction chemotherapy. However, the regimen received (BEP vs. EP) did maintain important differences in RP histology outcomes and survival. For example, in an evaluation of only patients who received chemotherapy outside Indiana University, the EP Â 4 group still had significantly more residual cancer in the RP compared with the BEP Â 3 group (31% vs. 9%; P ¼ .002). Conversely, when patients treated with BEP were assessed, regardless of treating institution, there were no statistical differences in RP histology between those who received BEP at Indiana University (2%) compared with those who received it at an outside institution (9%; P ¼ .29). Furthermore, the KaplaneMeier OS results remained significantly worse for the EP group when limited to patients who received their chemotherapy outside Indiana University ( Figure 3A) . Moreover, the survival curves of patients treated with BEP at Indiana University compared with those treated with BEP at outside institutions are essentially mirror images of each other.
This retrospective study does have limitations worth highlighting. First, we were unable to control for variance in treatment regimens (ie, dose reductions) and could not describe overall response rates apart from the PC-RPLND patients. There was also a referral and selection bias of patients referred and treated at our institution. Nevertheless, it is our belief that this subset of goodrisk patients can guide our current understanding on the subject. Because it is difficult to power a study adequately to detect significant differences in OS, studying patients with residual tumors after chemotherapy can be a surrogate for subsequent salvage therapy. Second, the limited number of deaths in this good risk cohort of patients reduced any definitive conclusion to be drawn from these results. However, this trend of numerically worse outcomes in the EP Â 4 group adds to similarly published outcomes. Third, a number of these patients received their induction chemotherapy at an outside institution. None of the 45 patients in the EP group received chemotherapy at Indiana University and only 27% (48 of 178) received BEP Â 3 at our institution. Recent criticism has suggested that this accounts for the difference observed between the groups because of the relative dose intensity delivered. 12 However, the sensitivity analyses showed similar RP histology and survival outcomes in the BEP group regardless of whether they were treated at Indiana University or elsewhere. Although patients with IGCCCG poor-risk features have been shown to have worse survival when treated at low volume centers, 13 it might not be prudent to assume that a significant portion of this good-risk population treated at lower volume centers received inadequate care. These limitations notwithstanding, our findings have significant implications for patients and providers. In this cohort of good-risk patients, there are clear differences in the RP histology between the 2 chemotherapy regimens with a higher incidence of residual germ cell cancer in the EP group. This can influence the necessity for additional chemotherapy with its subsequent additive long-term side effects and can ultimately affect survival. Because a future randomized trial in this setting is unlikely to occur, these data provide medical oncologists with histologic and survival outcomes in a comparison of the 2 chemotherapy regimens, which can assist in decision-making and counseling of patients. One caveat in which we would prefer EP Â 4 rather than BEP Â 3 is in patients older than the age of 50 years, regardless of smoking history.
Conclusion
Good-risk testicular cancer patients who received BEP Â 3 had less residual cancer in the RP specimen at the time of PC-RPLND. It is less clear if this leads to an improvement in survival compared with those who received EP Â 4 as induction chemotherapy in this retrospective analysis. We continue to favor BEP Â 3 as induction chemotherapy in good-risk patients assuming there are no underlying lung conditions and patients are younger than 50 years of age.
Clinical Practice Points
Although not statistically significant, there is a numerically worse survival when good-risk patients are treated with EP Â 4 compared with BEP Â 3.
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Treating institution did not seem to have an effect on survival in good-risk patients in a comparison of BEP chemotherapy regimens.
